Stockscreener 앱 받기
258.13
4.74%
-12.85
시간 외 거래:
261.80
3.67
+1.42%
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen - Seeking Alpha
PRAX Adjusts EMBRAVE3 Study Design After FDA Meeting - GuruFocus
Praxis Precision Medicines Announces FDA Approval for EMBRAVE3 Trial Design Change for Elsunersen in SCN2A Developmental and Epileptic Encephalopathy - Quiver Quantitative
Praxis Precision Medicines announces alignment with FDA - marketscreener.com
PRAX Stock Research: Jefferies Raises Price Target by 50% on Dec - GuruFocus
Praxis Precision (NASDAQ: PRAX) gets FDA nod for single-arm Elsunersen EMBRAVE3 trial - Stock Titan
Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. $PRAX Shares Bought by Swiss National Bank - MarketBeat
Praxis Precision Medicine (PRAX): Guggenheim Raises Price Target to $760 | PRAX Stock News - GuruFocus
Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN
Praxis Precision Medicines, Inc. $PRAX Stock Holdings Boosted by B Group Inc. - MarketBeat
Best Pharmaceutical Stocks To Watch TodayDecember 5th - MarketBeat
Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins - Insider Monkey
BTIG maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN
PRAX Stock Surge: Rally or Risk? - StocksToTrade
Praxis Precision Medicines reports clinical updates on epilepsy drug candidates - Investing.com Nigeria
Praxis Precision Medicines Shares RADIANT Study Results - TipRanks
TD Cowen Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Finviz
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $353.00 - MarketBeat
TD Cowen Raises Price Target for PRAX to $353, Maintains Buy Rat - GuruFocus
Truist Securities Raises Price Target for PRAX to $500 | PRAX St - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Given New $500.00 Price Target at Truist Financial - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 9.2% Following Analyst Upgrade - MarketBeat
Needham raises Praxis Precision Medicines stock price target on improved data - Investing.com Nigeria
Praxis Precision Medicines stock price target raised to $353 from $251 at TD Cowen - Investing.com UK
Truist Securities raises Praxis Precision Medicines stock price target to $500 - Investing.com Nigeria
Guggenheim raises Praxis Precision Medicines stock price target to $760 on strong epilepsy data By Investing.com - Investing.com South Africa
PRAX Releases Promising Clinical Updates on Epilepsy Treatments - GuruFocus
Praxis Precision Medicine (PRAX) Sees Raised Price Target by Nee - GuruFocus
Needham & Company LLC Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Praxis Precision Medicines Reports Positive EMBOLD and RADIANT Study Results for Relutrigine and Vormatrigine in Epilepsy Treatment - Quiver Quantitative
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies - The Manila Times
Truist Raises Price Target on Praxis Precision Medicines to $500 From $360, Keeps Buy Rating - marketscreener.com
HC Wainwright Reiterates 'Buy' Rating on PRAX with $340 PT | PRA - GuruFocus
Praxis (NASDAQ: PRAX) posts 53% seizure drop in EMBOLD trial, plans FDA NDA talks - Stock Titan
Guggenheim raises Praxis Precision Medicines stock price target to $760 on strong epilepsy data - Investing.com Australia
BTIG Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
PRAX: BTIG Raises Price Target to $507 with Buy Rating | PRAX St - GuruFocus
Praxis Precision Medicines (PRAX) Gaining Confidence on EMBOLD Study Optimism - Insider Monkey
Kennedy Capital Management LLC Increases Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 52-Week HighWhat's Next? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines (PRAX): Reassessing Valuation After EMBOLD Success and Ulixacaltamide Pre-NDA Milestone - Yahoo Finance
Capital Fund Management S.A. Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicine (PRAX) Target Price Raised by HC Wainw - GuruFocus
Praxis Precision Medicines stock hits 52-week high at $241.0 By Investing.com - Investing.com Nigeria
HC Wainwright & Co. maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN
Praxis Potential Breakthrough: Market Reactions - StocksToTrade
Another Praxis win provides much-needed progress in rare genetic epilepsies - BioCentury
PRAX Announces Breakthroughs in Neurological Treatments: Key Developments with FDA - StocksToTrade
Will Praxis Stock Climb Higher? - timothysykes.com
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle - BioWorld MedTech
Praxis Drug Trials Spark Optimism Amid Market Expansion - timothysykes.com
Praxis Precision Medicines Lights Up with Promising FDA Progress - timothysykes.com
How EMBOLD Efficacy Stop And Ulixacaltamide FDA Pathway At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story - Yahoo Finance
Uptick in Praxis Precision Medicines: What’s Next? - StocksToTrade
1.50%
자본화:
|
볼륨(24시간):